[{"id":"3235b46b-d9e7-4b97-b6a2-ee9db0199285","acronym":"","url":"https://clinicaltrials.gov/study/NCT06021379","created_at":"2023-09-01T17:11:35.240Z","updated_at":"2024-07-02T16:35:30.994Z","phase":"","brief_title":"AryoTrust® (Trastuzumab) Safety Study","source_id_and_acronym":"NCT06021379","lead_sponsor":"AryoGen Pharmed Co.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • AryoTrust (trastuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 597","initiation":"Initiation: 02/22/2017","start_date":" 02/22/2017","primary_txt":" Primary completion: 08/28/2022","primary_completion_date":" 08/28/2022","study_txt":" Completion: 08/28/2022","study_completion_date":" 08/28/2022","last_update_posted":"2023-10-31"},{"id":"c62b2a99-5cda-4aa9-9b42-213f745b51d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03425656","created_at":"2021-01-18T16:54:01.761Z","updated_at":"2024-07-02T16:36:43.373Z","phase":"Phase 3","brief_title":"Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer","source_id_and_acronym":"NCT03425656","lead_sponsor":"AryoGen Pharmed Co.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • AryoTrust (trastuzumab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 07/09/2016","start_date":" 07/09/2016","primary_txt":" Primary completion: 03/06/2018","primary_completion_date":" 03/06/2018","study_txt":" Completion: 08/05/2018","study_completion_date":" 08/05/2018","last_update_posted":"2020-07-10"}]